Kleo
Targeted immunotherapy company developing synthetic bispecific therapies to enhance antibody function.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
Related Content
Kleo Pharmaceuticals is a biotechnology company focused on developing targeted immunotherapies. The company specializes in creating synthetic bispecific therapies designed to emulate or enhance the function of natural antibodies. These therapies are aimed at treating various diseases, including multiple myeloma and COVID-19. Kleo Pharmaceuticals operates primarily in the biopharmaceutical market, serving healthcare providers and patients who require advanced therapeutic options. The company's business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary therapies. Revenue is generated through partnerships, grants, and future sales of approved treatments.
Keywords: targeted immunotherapy, synthetic bispecific therapies, antibodies, multiple myeloma, COVID-19, biotechnology, healthcare, biopharmaceutical, clinical trials, advanced therapeutics.